Literature DB >> 11044799

Hormonal factors influencing weight and growth pattern in craniopharyngioma.

G Pinto1, L Bussières, C Recasens, J C Souberbielle, M Zerah, R Brauner.   

Abstract

Patients operated on for craniopharyngioma frequently suffer from hyperphagia and are obese, but their statural growth is normal despite growth hormone (GH) deficiency. We have evaluated the hormonal factors influencing changes in weight and growth in 17 children before and 1, 3-6, 12, and/or 24 months after surgical resection of a craniopharyngioma performed at 7.7 +/- (SE) 1 years of age. Of these, 15 patients had a GH deficiency before surgery, and all had complete pituitary deficiency after it. The plasma fasting insulin concentrations before surgery were positively correlated with body mass index (BMI, kg/m(2); p < 0.05), plasma insulin-like growth factors (IGFI, p = 0.03, and IGFII, p = 0.04), and leptin (p = 0.03). They increased significantly 1 month after surgery and continued to increase thereafter, whereas leptin increased significantly only 3-6 months after surgery, paralleling changes in BMI. The plasma fasting insulin concentrations before surgery were also positively correlated with the weight changes (12.3 +/- 2.3 kg, p < 0.01) during the 12 months after surgery, but not with changes in BMI SDS (3.1 +/- 0.5, p = 0.07). Both expressions of weight change were correlated with the concomitant growth rates (4.8 +/- 0.7 cm, p < 0.01). IGFI was above the 10th percentile for children with idiopathic short stature in 10 of 15 patients with craniopharyngioma-induced GH deficiency and IGF-binding protein 3 in 14 of 15 patients. Craniopharyngioma itself modified the control of insulin secretion, and surgery increased the insulin secretion which continued in the same way in a given patient after surgery. The increased insulin secretion in turn increases weight and keeps IGFI nearly normal. This may explain the normal growth rate despite the complete lack of GH. Copyright 2000 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11044799     DOI: 10.1159/000023562

Source DB:  PubMed          Journal:  Horm Res        ISSN: 0301-0163


  7 in total

1.  Hyperinsulinemia may promote growth without GH in children after resection of suprasellar brain tumors.

Authors:  Hideyuki Iwayama; Takashi Kamijo; Norishi Ueda
Journal:  Endocrine       Date:  2011-06-03       Impact factor: 3.633

2.  GH secretion in a cohort of children with pseudohypoparathyroidism type Ia.

Authors:  L de Sanctis; J Bellone; M Salerno; E Faleschini; M Caruso-Nicoletti; M Cicchetti; D Concolino; A Balsamo; F Buzi; L Ghizzoni; C de Sanctis
Journal:  J Endocrinol Invest       Date:  2007-02       Impact factor: 4.256

3.  Practical approach to childhood craniopharyngioma: a role of an endocrinologist and a general paediatrician.

Authors:  Maria A Kalina; Eliza Skala-Zamorowska; Barbara Kalina-Faska; Ewa Malecka-Tendera; Marek Mandera
Journal:  Childs Nerv Syst       Date:  2009-06-17       Impact factor: 1.475

Review 4.  Review of physiology, clinical manifestations, and management of hypothalamic obesity in humans.

Authors:  Michelle Lee; Judith Korner
Journal:  Pituitary       Date:  2009       Impact factor: 4.107

5.  Hypothalamic obesity complicated by adipsic central diabetes insipidus following surgical resection of a craniopharyngioma.

Authors:  Kathleen Colleran; Leslie Sanchez-Goettler; Anita Sloan
Journal:  J Clin Hypertens (Greenwich)       Date:  2009-10       Impact factor: 3.738

6.  Hypothalamic obesity after craniopharyngioma: mechanisms, diagnosis, and treatment.

Authors:  Robert H Lustig
Journal:  Front Endocrinol (Lausanne)       Date:  2011-11-03       Impact factor: 5.555

7.  Childhood craniopharyngioma: greater hypothalamic involvement before surgery is associated with higher homeostasis model insulin resistance index.

Authors:  Christine Trivin; Kanetee Busiah; Nizar Mahlaoui; Christophe Recasens; Jean-Claude Souberbielle; Michel Zerah; Christian Sainte-Rose; Raja Brauner
Journal:  BMC Pediatr       Date:  2009-04-02       Impact factor: 2.125

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.